STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
Y
Suspended
- Recurrent B-Cell Non-Hodgkin Lymphoma
- +23 more
- Lenalidomide
- +2 more
- Columbus, OhioOhio State University Comprehensive Cancer Center
2022-02-23
Feb 23, 2022C
Active, not recruiting
- Grade 3b Follicular Lymphoma
- +15 more
- Laboratory Biomarker Analysis
- +2 more
- Duarte, CaliforniaCity of Hope Medical Center
2022-02-17
Feb 17, 2022B
Recruiting
- Diffuse Large B-Cell Lymphoma
- +14 more
- La Jolla, California
- +1 more
2022-01-10
Jan 10, 2022N
Terminated
- Adult Grade III Lymphomatoid Granulomatosis
- +116 more
- brentuximab vedotin
- +2 more
- Chicago, Illinois
- +2 more
2021-08-30
Aug 30, 2021D
Recruiting
- Lymphoma
- Survivorship
- Interview with Clinicians
- +2 more
- Boston, MassachusettsDana-Farber Cancer Institute
2022-03-14
Mar 14, 2022U
Recruiting
- B-Cell Non-Hodgkin Lymphoma
- +7 more
- Acalabrutinib
- Axicabtagene Ciloleucel
- Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
2022-03-16
Mar 16, 2022N
Active, not recruiting
- Recurrent Diffuse Large B-Cell Lymphoma
- +8 more
- Ibrutinib
- +2 more
- Chicago, Illinois
- +2 more
2022-04-05
Apr 5, 2022J
Recruiting
- Relapsed Plasmablastic Lymphoma
- +2 more
- Belantamab Mafodotin
- Boston, Massachusetts
- +2 more
2021-09-20
Sep 20, 2021N
Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma
Not yet recruiting
- Recurrent Angioimmunoblastic T-Cell Lymphoma
- +13 more
- Brentuximab Vedotin
- Pembrolizumab
- Chicago, IllinoisNorthwestern University
2022-01-24
Jan 24, 2022N
Active, not recruiting
- Non-Hodgkin Lymphoma
- +4 more
- Pembrolizumab
- Bethesda, MarylandNational Institutes of Health Clinical Center
2022-04-07
Apr 7, 2022A
Not yet recruiting
- AIDS-Related Diffuse Large B-cell Lymphoma
- +14 more
- Axicabtagene Ciloleucel
- +2 more
- (no location specified)
2022-02-15
Feb 15, 2022W
Terminated
- Follicular Lymphoma
- Mantle Cell Lymphoma
- New York, New YorkWeill Cornell Medicine
2021-09-20
Sep 20, 2021J
Recruiting
- Indolent B-Cell Non-Hodgkin Lymphoma
- +18 more
- Lenalidomide
- +2 more
- Sacramento, CaliforniaUniversity of California Davis Comprehensive Cancer Center
2021-12-17
Dec 17, 2021M
Active, not recruiting
- Adult Nasal Type Extranodal NK/T-cell Lymphoma
- +20 more
- panobinostat
- +6 more
- Scottsdale, Arizona
- +1 more
2022-02-03
Feb 3, 2022M
Active, not recruiting
- Ann Arbor Stage II Follicular Lymphoma
- +9 more
- Ibrutinib
- +3 more
- Houston, TexasM D Anderson Cancer Center
2022-02-03
Feb 3, 2022U
Recruiting
- Non-hodgkin Lymphoma
- +2 more
- Radiation - Dose Level 0
- +4 more
- Chicago, IllinoisUniversity of Chicago
2021-12-03
Dec 3, 2021M
Completed
- Lymphoma
- 3RP-Lymphoma
- Boston, MassachusettsMassachusetts General Hospital
2021-11-09
Nov 9, 2021B
Completed
- Marginal Zone Lymphoma
- +2 more
- Harbin, Heilongjiang, China
- +3 more
2021-10-26
Oct 26, 2021M
Withdrawn
- Lymphoma
- Home Hospital for Lymphoma
- Boston, MassachusettsMassachusetts General Hospital Cancer Center
2021-08-31
Aug 31, 2021S
Completed
- Relapsed or Refractory Anaplastic Large Cell Lymphoma & Hodgkin Lymphoma
- Seoul, Gangnam-Gu, Korea, Republic ofSamsung Medical Center
2022-02-04
Feb 4, 2022U
Active, not recruiting
- Non Hodgkin Lymphoma
- +8 more
- Miami, Florida
- +2 more
2022-03-08
Mar 8, 2022M
Terminated
- Central Nervous System Lymphoma
- +6 more
- Akt/ERK Inhibitor ONC201
- +2 more
- Houston, TexasM D Anderson Cancer Center
2022-03-30
Mar 30, 2022E
Recruiting
- Grade 1 Follicular Lymphoma
- +7 more
- Acalabrutinib
- +3 more
- Atlanta, GeorgiaEmory University Hospital/Winship Cancer Institute
2021-12-07
Dec 7, 2021C
Recruiting
- Recurrent B-Cell Non-Hodgkin Lymphoma
- +19 more
- CpG-STAT3 siRNA CAS3/SS3
- Radiation Therapy
- Duarte, CaliforniaCity of Hope Medical Center
2022-02-28
Feb 28, 2022I
Recruiting
- Diffuse Large B-cell Lymphoma
- Patient with histologically confirmed diffuse large B-cell lymphoma with a planned first line treatment by R-CHOP.
- Toulouse, FranceInstitut Universitaire du Cancer Toulouse - Oncopole
2022-03-28
Mar 28, 2022